Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 02, 2026
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 29, 2026
TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 21, 2025
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Journal: JCO precision oncology
Published: November 20, 2025
Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas.
Journal: JCO precision oncology
Published: September 24, 2025
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer.
Journal: JCO precision oncology
Published: September 16, 2025
Analysis of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1), DLL3, OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumours.
Journal: Histopathology
Published: September 15, 2025
Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 22, 2025
Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms.
Journal: medRxiv : the preprint server for health sciences
Published: July 16, 2025
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
Journal: Journal for immunotherapy of cancer
Published: March 10, 2025
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 08, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 18, 2024
Last Updated: 09/26/2026